DadFinStart your free week
DadFin › Stocks › Healthcare › NPCE

NeuroPace, Inc. (NPCE) stock score

Healthcare · Medical Devices · United States

$7.97 ▲ +5.42% today

19.1
Dad Score, out of 100
weak

NeuroPace, Inc. (NPCE) is a Medical Devices company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 19.1 out of 100 on the Dad Score, a weak reading that places the business ahead of 19% of the 5,684 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #742 of 956. Its strongest axes are quality and liquidity; its weakest are valuation and price action.

Scores from the run of Nov 15, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Below average
Quality
Above average
Growth
Average
Price action
Weak
Risk
Weak
Conviction
Average
Liquidity
Strong
Macro
Below average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)—
P/E (forward)-23.6×
Dividend yield0.00%
Return on capital-16.0%
Operating margin-9.6%
Revenue growth (YoY)+25.1%
FCF yield-3.8%
Net debt / EBITDA3.00×
Piotroski F-Score5 / 9
52-week change-41.6%
Market cap$260M
Next earningsMar 2, 2027

What subscribers see on NPCE

Start your free weekSubscriber? Open the full research →

Medical Devices peers

StockCompanyDad ScoreBandMarket cap
ABTAbbott Laboratories92.5strong$188.0B
MDTMedtronic plc100.0strong$131.6B
SYKStryker Corporation75.9good$117.9B
BSXBoston Scientific Corporation88.2strong$64.3B
EWEdwards Lifesciences Corporation90.6strong$61.6B
GEHCGE HealthCare Technologies Inc.98.1strong$37.5B
DXCMDexCom, Inc.75.4good$31.1B
PHGKoninklijke Philips N.V.90.7strong$29.7B

Prices from DadFin's live feed (refreshed about every 30 minutes in the session); scores from the weekly run of Nov 15, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.